SCHEMBL4893835

SCHEMBL4893835

Cc1cc(C(C)(C)C)c(O)c(S(=O)(=O)Nc2ccc(C#N)cc2Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.57
ACLY P53396 4/20 0.46
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
HSD17B2 P37059 2/20 0.40
CCR9 P51686 3/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
TBXA2R P21731 1/20 0.39
TSHR P16473 2/20 0.39
CNR2 P34972 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898138 0.89 SLC22A12 (0.57) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL4893777 0.88 SLC22A12 (0.56) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL14023341 0.87 SLC22A12 (0.55) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL4890184 0.85 SLC22A12 (0.59) SLC22A12ACLY
SCHEMBL14023342 0.84 SLC22A12 (0.55) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL4885016 0.83 BRD4 (0.53) SLC22A12HSD17B2GAAALDH1A1TSHR
SCHEMBL4896279 0.83 SLC22A12 (0.52) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL4886491 0.79 SLC22A12 (0.45) SLC22A12ACLYPDK1PDK2PDK3
SCHEMBL4893211 0.79 CRHBP (0.57) ACLYHSD17B2MAPK1GAAHPGD
SCHEMBL6831807 0.78 MAPT (0.54) SLC22A12GAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US claimed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP claimed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS SLC22A12 1558/4885ACLY 167/4885PDK1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.